Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update – New Real World Study of 150,000 Patients Favors Caldolor over ketorolac – – DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations – NASHVILLE, TENNESSEE (Thursday, November 7, 2024) – Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9.1 million during the third quarter of ...